Single and Multiple Dose Study in Japanese

Inclusion Criteria: * Able to understand the study procedures, the risks involved and willing to provide written Informed Consent before the first study related activity. * Healthy adult subjects born in Japan * All laboratory parameters should be within normal limits or considered not clinically significant by the investigator. * Screening serum uric acid level \>= 4.5 mg/dL. * Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures. * Subject does not have clinically relevant abnormalities in blood pressure, heart rate, body temperature, and respiratory rate, as per the Investigator's judgment. Exclusion Criteria: * Positive serology to Human Immunodeficiency Virus (HIV-1 and HIV-2). * Positive test for active Hepatitis B or Hepatitis C infection. * History of kidney stones. * Undergone major surgery within 3 months of Day 1. * Subject has received the last dose of an investigational drug (or treatment with a medical device) within 30 days or 5 half-lives (whichever is longer) of the investigational drug prior to Day 1 or are currently participating in another study of an investigational drug (or medical device). * Prior exposure to lesinurad (RDEA594) or RDEA806.